170 related articles for article (PubMed ID: 38672534)
1. A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors.
McLean LS; Lim AM; Angel C; Young RJ; Pizzolla A; Archer S; Solomon BJ; Thai AA; Lewin J; Rischin D
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672534
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Frigola J; Navarro A; Carbonell C; Callejo A; Iranzo P; Cedrés S; Martinez-Marti A; Pardo N; Saoudi-Gonzalez N; Martinez D; Jimenez J; Sansano I; Mancuso FM; Nuciforo P; Montuenga LM; Sánchez-Cespedes M; Prat A; Vivancos A; Felip E; Amat R
Mol Oncol; 2021 Apr; 15(4):887-900. PubMed ID: 33342055
[TBL] [Abstract][Full Text] [Related]
4. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
Zhong YM; Yin K; Chen Y; Xie Z; Lv ZY; Yang JJ; Yang XN; Zhou Q; Wang BC; Zhong WZ; Gao LL; Zhou WB; Chen J; Tu HY; Liao RQ; Zhang DK; Zhang SL; Lu DX; Zheng HB; Zhang HH; Wu YL; Zhang XC
Front Immunol; 2022; 13():951817. PubMed ID: 36263036
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Yoh K; Matsumoto S; Furuya N; Nishino K; Miyamoto S; Oizumi S; Okamoto N; Itani H; Kuyama S; Nakamura A; Nishi K; Fukuda I; Tsuta K; Hayashi Y; Motoi N; Ishii G; Goto K
Lung Cancer; 2021 Sep; 159():128-134. PubMed ID: 34333203
[TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
11. Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Li L; Lu G; Liu Y; Gong L; Zheng X; Zheng H; Gu W; Yang L
Front Oncol; 2021; 11():658690. PubMed ID: 34150625
[TBL] [Abstract][Full Text] [Related]
12. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
13. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
[TBL] [Abstract][Full Text] [Related]
14. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
Ricciuti B; Wang X; Alessi JV; Rizvi H; Mahadevan NR; Li YY; Polio A; Lindsay J; Umeton R; Sinha R; Vokes NI; Recondo G; Lamberti G; Lawrence M; Vaz VR; Leonardi GC; Plodkowski AJ; Gupta H; Cherniack AD; Tolstorukov MY; Sharma B; Felt KD; Gainor JF; Ravi A; Getz G; Schalper KA; Henick B; Forde P; Anagnostou V; Jänne PA; Van Allen EM; Nishino M; Sholl LM; Christiani DC; Lin X; Rodig SJ; Hellmann MD; Awad MM
JAMA Oncol; 2022 Aug; 8(8):1160-1168. PubMed ID: 35708671
[TBL] [Abstract][Full Text] [Related]
15. The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China.
Chen Y; Wang Y; Luo H; Meng X; Zhu W; Wang D; Zeng H; Zhang H
Exp Hematol Oncol; 2020; 9():17. PubMed ID: 32775040
[TBL] [Abstract][Full Text] [Related]
16. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.
Mitchell KG; Negrao MV; Parra ER; Li J; Zhang J; Dejima H; Vaporciyan AA; Swisher SG; Weissferdt A; Antonoff MB; Cascone T; Roarty E; Wistuba II; Heymach JV; Gibbons DL; Zhang J; Sepesi B
Ann Thorac Surg; 2020 Feb; 109(2):358-366. PubMed ID: 31550464
[TBL] [Abstract][Full Text] [Related]
17. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
Sangro B; Melero I; Wadhawan S; Finn RS; Abou-Alfa GK; Cheng AL; Yau T; Furuse J; Park JW; Boyd Z; Tang HT; Shen Y; Tschaika M; Neely J; El-Khoueiry A
J Hepatol; 2020 Dec; 73(6):1460-1469. PubMed ID: 32710922
[TBL] [Abstract][Full Text] [Related]
18. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
19. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
20. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
